Twist Bioscience Corporation TWST
As ofNov 20, 2026, 11:42 AM EST
- YTD
- +230.23%
- 1 year
- +301.80%
5D -1.18 (-1.12%)
- Market cap
- 7.14B
- Revenue (ttm)
- 459.43M
- Profit margin
- -28.34%
- EPS (ttm)
- -2.08
- Shares out
- 68.18M
- Forward P/E
- 1708.56
- YTD return
- +230.23%
- 1-year return
- +301.80%
- 50-day average
- 149.33
- 200-day average
- 94.23
- Volume
- 1.01M
- Avg volume
- 2.46M
- Open
- 108.39
- Previous close
- 111.62
- Day's range
- 101.00 – 108.50
- 52-week range
- 25.67 – 219.71
- Beta
- 2.22
- Analysts
- Buy
- Price target
- 128.92 (+23.1%)
- Earnings date
- Feb 1, 2027
Key statistics
- Enterprise value
- 7.46B
- Price / sales
- 16.56
- Price / book
- 8.52
- Revenue growth
- 27.90%
- Free cash flow
- -55.86M
- Total cash
- 581.91M
- Total debt
- 109.98M
- Return on equity
- -19.13%
- Short % of float
- 18.19%
Fundamental scorecard
6 of 25 checks passed on TWST’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 45.00
- Target (mean)
- 128.92
- Target (high)
- 175.00
- Strong buy2
- Buy7
- Hold3
- Sell1
- Strong sell0
Next earnings
Feb 1, 2027
Expected Feb 1, 2027. Consensus EPS estimate -0.15033.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 1, 2027 | Dec 30, 2026 | -0.35 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -0.38707 | -0.32 | +0.07 | +17.33% |
| Aug 3, 2026 | Jun 30, 2026 | -0.50625 | -0.56 | -0.05 | -10.62% |
| May 4, 2026 | Mar 31, 2026 | -0.49 | -0.71 | -0.22 | -44.90% |
| Feb 2, 2026 | Dec 31, 2025 | -0.48 | -0.50 | -0.02 | -4.17% |
| Nov 14, 2025 | Sep 30, 2025 | -0.50 | -0.45 | +0.05 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 12, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 8, 2026 | Jefferies | init | — | Hold |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Leerink Partners | main | Outperform | Outperform |
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- twistbioscience.com
News
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $130
CrowdStrike To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday Leerink Partners Maintains Outperform on Twist Bioscience, Lowers Price Target to $175
TD Cowen Maintains Buy on Twist Bioscience, Lowers Price Target to $137
Cathie Wood Is Buying the CoreWeave Dip and Selling Palantir Canaccord Genuity Maintains Buy on Twist Bioscience, Lowers Price Target to $150
Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $135
Twist Bioscience 2027 Outlook Signals Sharp Slowdown in AI Drug Discovery Growth
Your note
Sign in to keep a note on TWST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAN NELSON C | Director | Stock Award(Grant) | Feb 4, 2026 | 33,251 |
| CHESS ROBERT BRUCE | Director | Conversion of Exercise of derivative security | Aug 6, 2026 | 63,612 |
| CHO DENNIS | Officer | Stock Award(Grant) | Nov 15, 2026 | 87,283 |
| CRANDELL KEITH L. | Director | Stock Award(Grant) | Feb 4, 2026 | 103,618 |
| FINN PATRICK JOHN | President | Stock Award(Grant) | Nov 15, 2026 | 239,367 |
| GREEN PAULA | Officer | Stock Award(Grant) | Nov 15, 2026 | 128,145 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.46% | 9,695,518 | 1.08B | Sep 29, 2026 |
| Blackrock Inc. | 10.18% | 6,386,116 | 712.82M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 9.70% | 6,084,852 | 679.19M | Sep 29, 2026 |
| ARK Investment Management, LLC | 5.42% | 3,398,057 | 379.29M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.98% | 3,122,452 | 348.53M | Sep 29, 2026 |
| State Street Corporation | 4.81% | 3,017,072 | 336.77M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 1,874,473 | 209.23M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.73% | 1,714,174 | 191.34M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 1,357,205 | 151.49M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.15% | 1,346,052 | 150.25M | Oct 30, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.91% | 1,194,813 | 133.37M | Oct 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.88% | 1,177,281 | 131.41M | Sep 29, 2026 |
